Annovis Bio (NYSE:ANVS – Get Free Report) and Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.
Insider and Institutional Ownership
15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 32.3% of Annovis Bio shares are held by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Annovis Bio and Regulus Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Annovis Bio | N/A | N/A | -$56.20 million | ($4.46) | -1.53 |
| Regulus Therapeutics | N/A | N/A | -$30.04 million | ($1.07) | -1.34 |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Annovis Bio and Regulus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Annovis Bio | 0 | 1 | 5 | 1 | 3.00 |
| Regulus Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
Annovis Bio currently has a consensus target price of $32.17, indicating a potential upside of 370.27%. Regulus Therapeutics has a consensus target price of $10.80, indicating a potential upside of 655.24%. Given Regulus Therapeutics’ higher possible upside, analysts plainly believe Regulus Therapeutics is more favorable than Annovis Bio.
Risk and Volatility
Annovis Bio has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Profitability
This table compares Annovis Bio and Regulus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Annovis Bio | N/A | -876.22% | -311.00% |
| Regulus Therapeutics | N/A | -53.07% | -48.58% |
Summary
Regulus Therapeutics beats Annovis Bio on 7 of the 11 factors compared between the two stocks.
About Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
About Regulus Therapeutics
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
